We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

16 hedge funds and large institutions have $215K invested in Hepion Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 16 → 16 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

36% less capital invested

Capital invested by funds: $338K → $215K (-$123K)

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$8.77K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$7.12K
3
Renaissance Technologies
Renaissance Technologies
New York
+$499

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$25.4K
2
Citadel Advisors
Citadel Advisors
Florida
-$19.6K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.16K
4
TRCT
Tower Research Capital (TRC)
New York
-$656
5
AF
Advisornet Financial
Minnesota
-$42
Name Holding Trade Value Shares
Change 		Change in
Stake
AFM
1
Anson Funds Management
Texas
$89.9K – – –
BlackRock
2
BlackRock
New York
$39K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$23.6K -$25.4K -813 -45%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$21.2K -$1.16K -37 -4%
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$12.2K +$7.12K +228 +78%
Renaissance Technologies
6
Renaissance Technologies
New York
$8.16K +$499 +16 +5%
State Street
7
State Street
Massachusetts
$7.37K – – –
UBS Group
8
UBS Group
Switzerland
$6.59K +$8.77K +281 New
PNC Financial Services Group
9
PNC Financial Services Group
Pennsylvania
$3.63K – – –
TRCT
10
Tower Research Capital (TRC)
New York
$2.74K -$656 -21 -15%
Morgan Stanley
11
Morgan Stanley
New York
$637 – – –
FDCDDQ
12
Federation des caisses Desjardins du Quebec
Quebec, Canada
$82 – – –
SS
13
SBI Securities
Japan
$59 +$94 +3 New
Osaic Holdings
14
Osaic Holdings
Arizona
$53 – – –
Group One Trading
15
Group One Trading
Illinois
$39 – – –
Bank of America
16
Bank of America
North Carolina
$26 – – –
Barclays
17
Barclays
United Kingdom
$8 – – –
AF
18
Allworth Financial
California
$1 – – –
Citadel Advisors
19
Citadel Advisors
Florida
– -$19.6K -586 Closed
AF
20
Advisornet Financial
Minnesota
– -$42 -1 Closed

HEPA Hedge Fund Activity: Q4 2024 in Review

16 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2024, worth a combined $215K — down 36% from $338K a quarter earlier.

Fund positioning in HEPA was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 3 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $8.77K. The largest seller was Vanguard Group, cutting an estimated $25.4K.

  • 16 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $215K of Hepion Pharmaceuticals stock for Q4 2024, down 36% quarter-over-quarter.
  • 2 funds opened new Hepion Pharmaceuticals positions in Q4 2024 and 2 closed out, a net change of 0 holders.
  • The largest Hepion Pharmaceuticals buyer in Q4 2024 was UBS Group, an estimated $8.77K added.
  • The largest Hepion Pharmaceuticals seller in Q4 2024 was Vanguard Group, an estimated $25.4K sold.

Based on aggregated 13F filings for Q4 2024.